CRISPR Therapeutics AG (NASDAQ:CRSP) and Cyclerion Therapeutics Inc. (NASDAQ:CYCN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of the two firms.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||59||0.00||34.37M||-0.46||0.00|
|Cyclerion Therapeutics Inc.||3||0.00||22.84M||-4.67||0.00|
Demonstrates CRISPR Therapeutics AG and Cyclerion Therapeutics Inc. earnings per share, gross revenue and valuation.
Table 2 shows CRISPR Therapeutics AG and Cyclerion Therapeutics Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,959,527.82%||-2.6%||-2%|
|Cyclerion Therapeutics Inc.||794,103,330.78%||-211.2%||-110.6%|
The Current Ratio and Quick Ratio of CRISPR Therapeutics AG are 8.3 and 8.3 respectively. Its competitor Cyclerion Therapeutics Inc.’s Current Ratio is 6.3 and its Quick Ratio is 6.3. CRISPR Therapeutics AG can pay off short and long-term obligations better than Cyclerion Therapeutics Inc.
The following table delivered below contains the ratings and recommendations for CRISPR Therapeutics AG and Cyclerion Therapeutics Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Cyclerion Therapeutics Inc.||0||0||0||0.00|
CRISPR Therapeutics AG has a 10.16% upside potential and an average price target of $72.
Insider and Institutional Ownership
Roughly 46.8% of CRISPR Therapeutics AG shares are owned by institutional investors while 73.2% of Cyclerion Therapeutics Inc. are owned by institutional investors. Insiders owned roughly 0.4% of CRISPR Therapeutics AG’s shares. Insiders Competitively, owned 1.6% of Cyclerion Therapeutics Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Cyclerion Therapeutics Inc.||2.16%||-10.43%||-81.91%||-80.87%||0%||-84.88%|
For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Cyclerion Therapeutics Inc. has -84.88% weaker performance.
CRISPR Therapeutics AG beats Cyclerion Therapeutics Inc. on 8 of the 10 factors.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.